Head-to-head · WeighScore
Ivim Health vs Trellis Vitality
By GLP-1 ScorecardUpdated
Score comparison
Trellis Vitality has the higher recorded score — 73.4/100 to 59.6/100.
Trellis Vitality grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Trellis Vitality lists one-, three- and six-month GLP-1 plans, with lower monthly figures for longer terms. Confirm the actual charge and shipment schedule before enrolling.
Before you choose
Before comparing the headline prices, the Ivim Health review and the Trellis Vitality review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Auren Rx vs Ivim Health and Jently vs Trellis Vitality compare each of them with another graded program, and the list of alternatives to Ivim Health ranks the programs closest to Ivim Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the System Labs review covers one graded close to these two, at 68.4/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Ivim Health | Trellis Vitality |
|---|---|---|
| WeighScore | 59.6/100 | 73.4/100 |
| Grade | C | C |
| Site position | #369 | #77 |
| Semaglutide | $149/mo (starting dose, medication and program fee, compounded) | $150/mo (one-month plan; lower monthly figures for longer plans) |
| Tirzepatide | $224/mo (starting dose, medication and program fee, compounded) | $199/mo (one-month plan; lower monthly figures for longer plans) |
| Coverage | Coverage not published | All 50 states claimed; treatment availability varies |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Both molecules are priced on one page, each quoted as medication and program charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
What to consider
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
- Both figures are 'starting at' rates, so the cost of a titrated dose is not published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Strengths
- Lists both medications in one table by plan length
- Advertises the same price across available dosages
- Identifies Vials Rx on the GLP-1 page
What to consider
- Longer-plan monthly figures do not establish the debit or shipping schedule
- Refund eligibility is determined per order
- State availability can vary by medication and formulation
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.